NCT06887192 - A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions

Psychosis Associated With Alzheimer's Disease

Interventions

DRUG

ML-007C-MA

ML-007C-MA dosed as 105/1.5 mg (one tablet of 105/1.5 mg ML-007C-MA), or 210/3 mg (two tablets of 105/1.5 mg ML-007C-MA )

DRUG

Placebo

Placebo Tablets

Trial Locations (16)

33014

RECRUITING

Clinical Site, Miami Gardens

33104

RECRUITING

Clinical Site, Miami Gardens

33155

RECRUITING

Clinical Site, Miami

33173

RECRUITING

Clinical Site, Miami

33186

RECRUITING

Clinical Site, Miami

33407

RECRUITING

Clinical Site, West Palm Beach

33428

RECRUITING

Clinical Site, Boca Raton

34105

RECRUITING

Clinical Site, Naples

44131

RECRUITING

Clinical Site, Independence

85704

RECRUITING

Clinical Site, Tucson

92805

RECRUITING

Clinical Site, Anaheim

92866

RECRUITING

Clinical Site, Orange

L6W 2Z8

NOT_YET_RECRUITING

Clinical Site, Brampton

N6A 5W9

RECRUITING

Clinical Site, London

M4N 3M5

RECRUITING

Clinical Site, Toronto

G6V 0C9

RECRUITING

Clinical Site, Lévis